Professor of Respiratory Medicine
Professor Pavord has a particular interest in asthma, chronic pulmonary disease and chronic cough. He is an internationally renowned researcher in these areas and has played a lead role in developing three of the most promising emerging treatments. He has published 350 scientific papers, including three of the 20 most cited papers in the field in the last 10 years. He has an H-index of 74. His main contribution has been to develop new methods to assess and treat airway inflammation and airway diseases.
He has been joint Chief Medical Advisor to Asthma UK since May 2008 and joint Editor of Thorax since 2010.
in 2016 Professor Pavord was awarded The ERS Gold Medal in Asthma in recognition of his outstanding contribution in the field of asthma research.
A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial
Hinks TSC. et al, (2020), Trials, 21
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
Moran AM. et al, (2020), American Journal of Respiratory and Critical Care Medicine, 202, 1314 - 1316
Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma.
Papi A. et al, (2020), The European respiratory journal
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Bourdin A. et al, (2020), Allergy
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Hippisley-Cox J. et al, (2020), Heart, 106, 1503 - 1511